Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is at the forefront of RNA interference (RNAi) therapeutics, pioneering a transformative class of medicines aimed at treating and potentially curing a wide range of diseases. Founded in 2002 and based in Cambridge, MA, Alnylam has translated Nobel Prize-winning science into five commercial products: ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), developed and commercialized in partnership with Novartis. These breakthrough therapeutics address conditions such as hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia.
Alnylam is dedicated to expanding its pipeline with several investigational medicines in late-stage development, focusing on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. The company’s commitment to sustainable innovation is reflected in its robust product pipeline and strategic collaborations with industry leaders like Roche and Regeneron.
Financially, Alnylam reported robust growth in 2023 with $1.24 billion in global net product revenues, a reflection of its strong commercial execution across its therapeutic products. The company maintains a strong cash position, bolstered by upfront fees from research partnerships and milestone achievements.
Alnylam is also dedicated to corporate responsibility, with initiatives aimed at reducing greenhouse gas emissions, promoting diversity and inclusion in clinical trials, and expanding global health equity through its Alnylam Challengers program. The company’s environmental impact data is third-party verified, underscoring its commitment to transparency and sustainability.
Looking ahead, Alnylam aims to sustain its leadership in RNAi therapeutics with the anticipated release of topline results from the HELIOS-B Phase 3 study and the continued development of promising candidates like zilebesiran for hypertension and mivelsiran for Alzheimer’s disease. For more details on Alnylam’s people, science, and pipeline, visit www.alnylam.com.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has published its first Corporate Responsibility (CR) Summary, outlining its environmental, social, and governance (ESG) standards. Key commitments include increasing minority participation in clinical trials, promoting female leadership, and enhancing employee support programs. The report emphasizes Alnylam's dedication to sustainability and accountability, led by a new CR Committee. It marks a significant step toward the company's vision of becoming a top 5 biotech firm while adhering to its core values.
Soleo Health has joined the treatment center directory for GIVLAARI (givosiran), enabling it to administer this FDA-approved therapy for adults with Acute Hepatic Porphyria (AHP). GIVLAARI is the first approved treatment for AHP, which causes the buildup of neurotoxins. Soleo Health offers injections in-home or at its infusion centers, utilizing its experience in specialty pharmacy. This partnership enhances Soleo's portfolio in treating rare diseases and utilizes SoleMetrics to collect valuable patient data over time.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present at three upcoming virtual conferences. The events are the Cowen 41st Annual Healthcare Conference on March 1 at 2:40 pm ET, the H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 am ET, and the Barclays Global Healthcare Conference on March 10 at 1:15 pm ET. Each presentation will have a live audio webcast available on the Company’s website, with replays accessible within 48 hours.
Alnylam specializes in RNA interference therapeutics aimed at treating various severe diseases.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced a company overview presentation at the 10th Annual SVB Leerink Global Healthcare Conference, scheduled for February 25, 2021, at 11:20 am ET. A live audio webcast will be accessible on the Investors section of Alnylam's website, with a replay available 48 hours post-event.
Alnylam is a leader in RNA interference therapeutics, developing innovative medicines for various diseases. Its current products include ONPATTRO, GIVLAARI, and OXLUMO, among others.
Alnylam Pharmaceuticals (Nasdaq: ALNY) reported strong financial results for Q4 and full year 2020, showcasing significant growth in product revenues amid regulatory approvals. ONPATTRO achieved $306 million in annual revenue, marking over 80% growth from 2019, while GIVLAARI brought in $55 million in its launch year. The company expects combined 2021 product revenues between $610 million and $660 million, indicating over 75% growth from 2020. Key developments included positive Phase 3 results for vutrisiran and the launch of OXLUMO. Alnylam anticipates continued expansion and product launches in 2021.
Alnylam Pharmaceuticals (Nasdaq: ALNY) is set to announce financial results for Q4 and the full year ending December 31, 2020, on February 11, 2021. The conference call will occur at 8:30 am ET, discussing performance and future expectations. Investors can access the live audio webcast through their website. Alnylam, founded in 2002, focuses on RNA interference therapeutics, including products like ONPATTRO, GIVLAARI, and OXLUMO. The company’s innovative pipeline aims to address rare and common diseases, underpinned by a robust financial outlook and strategic growth initiatives.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced its 5-year strategy named Alnylam P5x25, aiming to be among the top 5 biotech firms by market capitalization. Key goals include reaching over 0.5 million patients on its RNAi therapeutics, marketing at least 6 products, and achieving ≥40% revenue CAGR through 2025. Preliminary Q4 2020 revenues for ONPATTRO and GIVLAARI were approximately $90 million and $22 million, respectively, marking significant growth and strong demand for its therapies.
Alnylam Pharmaceuticals (Nasdaq: ALNY) announced positive results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic for hATTR amyloidosis. The study met primary and secondary endpoints, showing significant improvements in neurologic impairment and quality of life at 9 months, with a favorable safety profile. The company plans to submit a New Drug Application (NDA) to the FDA in early 2021 and expects additional regulatory filings globally. Vutrisiran's promising results position it as a potential treatment for this serious condition.
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:20 am ET, discussing unaudited fourth quarter and full year 2020 revenues. A Q&A breakout session will follow at 8:40 am ET. Investors can access a live audio webcast on the company's website, with a replay available within 48 hours. Alnylam is a leader in RNA interference therapeutics, working to develop innovative treatments for rare diseases.
Alnylam Pharmaceuticals (Nasdaq: ALNY) appointed Tolga Tanguler as Chief Commercial Officer, effective January 5, 2021. Tanguler brings over 20 years of experience from Pfizer and Alexion, where he significantly drove product launches and revenue growth. Alongside Tanguler, Alnylam expanded its leadership team with Kasha Witkos, Salil Patel, and Agnieszka Gallagher, enhancing its commercial and medical expertise. This strategic move aims to support global product launches and advance Alnylam's robust pipeline while striving for profitability.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
What is Alnylam Pharmaceuticals known for?
What products has Alnylam commercialized?
What diseases do Alnylam’s products treat?
What are the recent financial achievements of Alnylam?
Who are Alnylam’s key strategic partners?
What environmental initiatives has Alnylam undertaken?
What is the Alnylam Challengers program?
What are some key pipeline developments for Alnylam?
Where is Alnylam Pharmaceuticals headquartered?
How can I learn more about Alnylam Pharmaceuticals?
